^
Association details:
| Biomarker: | HER-2 V777L |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Excerpt:
Five HER2 mutations were tested in NCI-H508 cells, and all mutations produced resistance to cetuximab and panitumumab. Cetuximab inhibited the growth of NCI-H508 parental cells (Supplementary Fig. S2A), whereas NCI-H508–HER2V777L and HER2WT cells grew in the presence of cetuximab.
DOI:
10.1158/2159-8290.CD-14-1211
